Outline of patents

Anixa Biosciences Announces European Patent Issued for its CAR-T Cancer Therapy

Thursday, March 4, 2021 - 1:30pm

The patent is titled, "METHODS AND COMPOSITIONS FOR TREATING CANCER," and the inventors are Drs.

Key Points: 
  • The patent is titled, "METHODS AND COMPOSITIONS FOR TREATING CANCER," and the inventors are Drs.
  • The patent is assigned to The Wistar Institute and Anixa Biosciences' majority-owned subsidiary, Certainty Therapeutics, Inc., which is the exclusive, world-wide licensee.
  • Dr. Amit Kumar, President and CEO of Anixa Biosciences, stated, "We are pleased that the European Patent Office (EPO) has issued this patent.
  • This patent will provide protection of our technology throughout the European Union, in addition to the existing protection from our issued patent in the United States.

Tricida Granted Additional U.S. Patent Covering Composition of Matter of Veverimer

Wednesday, March 3, 2021 - 1:30pm

The newly issued patent covers additional composition of matter claims for veverimer to 2038 and extends the Tricida patent portfolio, which is solely owned by the company, to a total of 210 patents in 49 different countries, including two previously issued U.S. composition of matter patents and four issued U.S. method of treatment patents which provide protection to 2034.

Key Points: 
  • The newly issued patent covers additional composition of matter claims for veverimer to 2038 and extends the Tricida patent portfolio, which is solely owned by the company, to a total of 210 patents in 49 different countries, including two previously issued U.S. composition of matter patents and four issued U.S. method of treatment patents which provide protection to 2034.
  • Tricida solely owns other patent applications relating to veverimer that are currently pending in Australia, Brazil, Canada, China, Europe, Hong Kong, India, Israel, Japan, Mexico, Republic of Korea, Russia, and the United States.
  • This new composition of matter patent will enable us to fully capitalize on veverimers U.S. potential into 2038, said Gerrit Klaerner, Ph.D., Tricidas Chief Executive Officer and President.
  • This patent adds four years of additional patent protection to our timeline to obtain the full value of veverimer.

DGAP-News: Virpax(R) Pharmaceuticals Inc.: Virpax Pharmaceuticals Announces Newly Issued Patent for Probudur(TM)

Tuesday, March 2, 2021 - 1:09pm

WEST CHESTER, PA, March 2, 2021 - Virpax(R) Pharmaceuticals Inc. ("Virpax" or the "Company") (NASDAQ:VRPX), a company specializing in developing pharmaceutical products for pain management, today announced that the United States Patent and Trademark Office issued US Patent No.

Key Points: 
  • WEST CHESTER, PA, March 2, 2021 - Virpax(R) Pharmaceuticals Inc. ("Virpax" or the "Company") (NASDAQ:VRPX), a company specializing in developing pharmaceutical products for pain management, today announced that the United States Patent and Trademark Office issued US Patent No.
  • This newly issued patent, which is owned by LipoCure Rx and exclusively licensed to Virpax, has 18 claims and expires in 2029.
  • "We are extremely pleased with the continued development of the patent portfolio for ProbudurTM, our long-acting anesthetic for postoperative pain management.
  • This newly issued patent further broadens our overall intellectual property portfolio," stated Anthony Mack, Chairman and CEO of Virpax.

Pointivo Lands Eighth Patent Increasing Coverage of the Drone Analytics Market

Tuesday, February 23, 2021 - 6:05pm

Once issued, Pointivo will own eight US patents, with several other US and foreign patent applications pending.

Key Points: 
  • Once issued, Pointivo will own eight US patents, with several other US and foreign patent applications pending.
  • This patent covers the ability to automatically generate engineering CAD drawings from imagery captured from drones and other devices.
  • New Pointivo patent covers ability to automatically generate engineering CAD drawings from imagery captured from drones.
  • Pointivo is a pioneer in the use of AI and computer vision to extract information from imagery derived from various capture methods.

Croatia grants Lleida.net a patent for its method of receiving certified emails

Tuesday, February 23, 2021 - 11:37am

This patent, granted in Zagreb by theCroatianState Intellectual Property Office (SIPO), is valid for 20 years.

Key Points: 
  • This patent, granted in Zagreb by theCroatianState Intellectual Property Office (SIPO), is valid for 20 years.
  • The grant follows a patent granted for this method by the European Patent and Trademark Office in 2019.
  • It is also the method used by the Spanish FootballLeague for its audiovisual rights auction.
  • Lleida.net, which has more than 3,000 shareholders, is listed on BME Growth in Madrid, the OTCQX index in New York and Euronext Growth in Paris.

Croatia grants Lleida.net a patent for its method of receiving certified emails

Tuesday, February 23, 2021 - 11:35am

This patent, granted in Zagreb by theCroatianState Intellectual Property Office (SIPO), is valid for 20 years.

Key Points: 
  • This patent, granted in Zagreb by theCroatianState Intellectual Property Office (SIPO), is valid for 20 years.
  • The grant follows a patent granted for this method by the European Patent and Trademark Office in 2019.
  • It is also the method used by the Spanish FootballLeague for its audiovisual rights auction.
  • Lleida.net, which has more than 3,000 shareholders, is listed on BME Growth in Madrid, the OTCQX index in New York and Euronext Growth in Paris.

GTT Group Releases 4th Quarter Patent Transaction Market Report (PTMR)

Tuesday, February 16, 2021 - 11:00am

PORTLAND, Ore., Feb. 16, 2021 /PRNewswire-PRWeb/ -- Global Technology Transfer Group, Inc. (GTT Group), a world leader in strategic patent analysis and patent transaction services, today makes available the Fourth Quarter 2020 Patent Transaction Market Report (PTMR) including the Patent Market Index (PMI) and the Patent Licensing Index (PLI) results.

Key Points: 
  • PORTLAND, Ore., Feb. 16, 2021 /PRNewswire-PRWeb/ -- Global Technology Transfer Group, Inc. (GTT Group), a world leader in strategic patent analysis and patent transaction services, today makes available the Fourth Quarter 2020 Patent Transaction Market Report (PTMR) including the Patent Market Index (PMI) and the Patent Licensing Index (PLI) results.
  • For more than a decade, GTT Group's Patent Transaction Market Report has been providing subscribers key data on the health of the patent marketplace.
  • Within the Patent Transaction Market Report, you will find the industry's benchmark indexes and forecasting that are essential to understanding the current market and planning for the future.
  • The Patent Market Index (PMI) tracks patent transaction activity and is reported quarterly in the Patent Transaction Market Report (PTMR).

Palatin Technologies Announces Filing of International Patent Application Claiming PL9643

Wednesday, February 10, 2021 - 12:30pm

Palatin recently reported positive results in its Phase 2 study of PL9643 for the treatment of Dry Eye Disease (DED).

Key Points: 
  • Palatin recently reported positive results in its Phase 2 study of PL9643 for the treatment of Dry Eye Disease (DED).
  • A Phase 2/3 clinical trial with PL9643 for the treatment of DED is currently planned for mid-2021.
  • The PCT application for PL9643 establishes the base for the presumptive patent term, and if a patent is granted which claims priority to this application, could provide patent protection for PL9643, and any product in which PL9643 is the active pharmaceutical ingredient, out to 2041, excluding any additional term for patent adjustment or patent term extension.
  • We anticipate filing patent applications in the United States, Europe and a number of additional regions and countries throughout the world.

Canntab Granted 2nd Patent For Immediate Release Cannabidiol Formulation Tablets

Monday, February 1, 2021 - 2:27pm

CA 3050150 to Canntab, related toits proprietary cannabidiol formulations with a priority date of January 23, 2017.

Key Points: 
  • CA 3050150 to Canntab, related toits proprietary cannabidiol formulations with a priority date of January 23, 2017.
  • The Company now has patent protection in Canada and the USA providing an international scope to the Company's expanding portfolio of issued patents."
  • Canntab has filed more than a dozen patent applications in the United States and Canada for which two have now been granted or allowed.
  • On September 21, 2020 Canntab had announced that pursuant to a filing made inMarch 2017, the U.S. Patent and Trademark Office (USPTO) had issued U.S. Patent No.

AKHAN Semiconductor Awarded Additional Major Patents in Taiwan & South Korea

Thursday, January 14, 2021 - 1:23pm

The patents cover additional claims for AKHANs next-generation N-type diamond semiconductor electronics materials and devices.

Key Points: 
  • The patents cover additional claims for AKHANs next-generation N-type diamond semiconductor electronics materials and devices.
  • The Taiwanese-issued patent, I711153, and South Korea-issued patent 10-2195950, are key additions to AKHANs breakthrough Miraj Diamond intellectual property portfolio.
  • It is the Companys fourth issued patent from Taiwan, the global leader in semiconductor chip manufacturing, and third issued patent from South Korea, another global leader in semiconductor foundry processing.
  • These patents will be critically important in advancing AKHANs partnerships and relationships with companies throughout Taiwan, South Korea, and the world.